These emerging therapies , Semaglutide , represent a remarkable advancement in managing metabolic dysfunction and conceivably associated ailments . These drugs are categorized as GLP-1 hormone agonists , indicating they function to emulate the body's GLP-1 peptide, enhancing glucose production and reducing appetite . Although Semaglutide each works